AI imaging software developer Elucid recently raised $80 million in series C funding, led by Elevage Medical Technologies, with additional participation from industry strategic and existing investors.
The company said this funding will help with the expansion of commercialization efforts to provide physicians and patients with critical information to combat heart disease. This round brings the company’s total funding to $121 million since inception.
Elucid’s software has 501(k) clearance by the U.S. Food and Drug Administration (FDA) and can characterize arterial plaque, simulating what pathologists would see under a microscope. The company is also pursuing an indication for non-invasive measurement of fractional flow reserve, derived from its PlaqueIQ technology, to measure coronary blockages and the extent of ischemia.
The company also announced that Kelly Huang, PhD, will join Elucid's board of directors.
